Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $184.00.

Several brokerages recently commented on JAZZ. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Barclays reiterated an "overweight" rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Finally, Truist Financial upped their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $107.51 on Friday. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a 50 day simple moving average of $108.55 and a two-hundred day simple moving average of $119.66. The company has a market capitalization of $6.51 billion, a price-to-earnings ratio of 14.33, a P/E/G ratio of 4.62 and a beta of 0.33. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business's quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.68 EPS. Analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the sale, the chief executive officer now owns 440,307 shares of the company's stock, valued at $54,487,991.25. The trade was a 0.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Seamus Mulligan acquired 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The stock was bought at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director now directly owns 100,000 shares in the company, valued at $9,826,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 3,000 shares of company stock worth $355,925. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Focus Partners Wealth purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $551,000. CX Institutional bought a new position in Jazz Pharmaceuticals in the 1st quarter worth $4,316,000. Atria Investments Inc boosted its holdings in Jazz Pharmaceuticals by 19.5% in the 4th quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock worth $336,000 after buying an additional 445 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Jazz Pharmaceuticals by 15.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock worth $75,801,000 after buying an additional 83,807 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Jazz Pharmaceuticals by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock valued at $58,835,000 after acquiring an additional 24,481 shares during the period. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.